Literature DB >> 11106654

Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein.

T Imamura1, H Izumi, G Nagatani, T Ise, M Nomoto, Y Iwamoto, K Kohno.   

Abstract

A nonhistone chromosomal protein, high mobility group (HMG) 1, is ubiquitous in higher eukaryotic cells and binds preferentially to cisplatin-modified DNA. HMG1 also functions as a coactivator of p53, a tumor suppressor protein. We investigated physical interactions between HMG1 and p53 and the influence of p53 on the ability of HMG1 to recognize damaged DNA. Using immunochemical coprecipitation, we observed binding of HMG1 and p53. Interaction between HMG1 and p53 required the HMG A box of HMG1 and amino acids 363-376 of p53. Cisplatin-modified DNA binding by HMG1 was significantly enhanced by p53. An HMG1-specific antibody that recognized the A box of this protein also stimulated cisplatin-modified DNA binding. These data suggest that an interaction with either p53 or antibody may induce conformational change in the HMG1 A box that optimizes DNA binding by HMG1. Interaction of p53 with HMG1 after DNA damage may promote activation of specific HMG1 binding to damaged DNA in vivo and provide a molecular link between DNA damage and p53-mediated DNA repair.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106654     DOI: 10.1074/jbc.M008143200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Interactions between p53, hMSH2-hMSH6 and HMG I(Y) on Holliday junctions and bulged bases.

Authors:  Deepa Subramanian; Jack D Griffith
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

2.  Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein.

Authors:  Kristine McKinney; Carol Prives
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

Review 3.  The role of chromatin proteins in DNA damage recognition and repair.

Authors:  Piotr Widlak; Monika Pietrowska; Joanna Lanuszewska
Journal:  Histochem Cell Biol       Date:  2006-01       Impact factor: 4.304

4.  The effect of PKC phosphorylation on the "architectural" properties of HMGB1 protein.

Authors:  Iva Ugrinova; Stanislava Zlateva; Evdokia Pasheva
Journal:  Mol Biol Rep       Date:  2012-06-28       Impact factor: 2.316

5.  Y box-binding protein-1 binds preferentially to single-stranded nucleic acids and exhibits 3'-->5' exonuclease activity.

Authors:  H Izumi; T Imamura; G Nagatani; T Ise; T Murakami; H Uramoto; T Torigoe; H Ishiguchi; Y Yoshida; M Nomoto; T Okamoto; T Uchiumi; M Kuwano; K Funa; K Kohno
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

6.  Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression.

Authors:  Hidetaka Uramoto; Hiroto Izumi; Gunji Nagatani; Haruki Ohmori; Naofumi Nagasue; Tomoko Ise; Takeshi Yoshida; Kosei Yasumoto; Kimitoshi Kohno
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

7.  High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs.

Authors:  Natalia Krynetskaia; Hongbo Xie; Slobodan Vucetic; Zoran Obradovic; Evgeny Krynetskiy
Journal:  Mol Pharmacol       Date:  2007-10-19       Impact factor: 4.436

8.  Analysis and verification of the HMGB1 signaling pathway.

Authors:  Haijun Gong; Paolo Zuliani; Anvesh Komuravelli; James R Faeder; Edmund M Clarke
Journal:  BMC Bioinformatics       Date:  2010-10-15       Impact factor: 3.169

9.  Life after death: targeting high mobility group box 1 in emergent cancer therapies.

Authors:  Z Sheng Guo; Zuqiang Liu; David L Bartlett; Daolin Tang; Michael T Lotze
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

10.  Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times.

Authors:  Gayathri T Selvarajah; Jolle Kirpensteijn; Monique E van Wolferen; Nagesha A S Rao; Hille Fieten; Jan A Mol
Journal:  Mol Cancer       Date:  2009-09-07       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.